PALISADE BIO, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
PALISADE BIO, INC. (PALI) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of 0.00% for the 12-month period ending 2015-12-31, per its 10-K filed 2016-03-14.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2016-03-14
- PALISADE BIO, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2015 was 0.00%, a 100.00% decline from fiscal 2014.
- PALISADE BIO, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2014 was 5.30%, a 46.46% decline from fiscal 2013.
- PALISADE BIO, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2013 was 9.90%.
- PALISADE BIO, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2012 was 0.00%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|
| 2015-12-31 | 0.00% 10-K · filed 2016-03-14 |
| 2014-12-31 | 5.30% 10-K · filed 2016-03-14 |
| 2013-12-31 | 9.90% 10-K · filed 2016-03-14 |
| 2012-12-31 | 0.00% 10-K · filed 2015-03-16 |
| 2011-12-31 | 0.00% 10-K · filed 2014-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |